| Market Cap | 71.07K | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -37.26M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -48.00% |
| Sales | 692.76k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -91.00% |
| Dividend | N/A | Price/Book | 0.00 | EPS next 5Y | 17.50% | 52W High Chg | -100.00% |
| Recommedations | - | Quick Ratio | 0.03 | Shares Outstanding | 118.45M | 52W Low Chg | 500.00% |
| Insider Own | - | ROA | -43.84% | Shares Float | 116.43M | Beta | -0.06 |
| Inst Own | 0.02% | ROE | - | Shares Shorted/Prior | 211.98K/101.16K | Price | 0.00060 |
| Gross Margin | 48.24% | Profit Margin | - | Avg. Volume | 15,802 | Target Price | - |
| Oper. Margin | -4,952.49% | Earnings Date | Jun 17 | Volume | 1,058 | Change | 0.00% |
Generex Biotechnology Corporation, through its subsidiaries, engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an oral insulin product. The company is also developing AE37, a synthetic peptide vaccine, which has completed Phase IIb clinical trial to stimulate a potent and specific immune response against tumors expressing the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, it develops, manufactures, and distributes rapid point-of-care in-vitro medical diagnostics for infectious diseases, such as human immunodeficiency virus, tuberculosis, malaria, hepatitis B, hepatitis C, syphilis, and others; and test kits and cassettes for testing infectious diseases, as well as Excellagen, a wound conforming gel. Further, the company is developing immunotherapeutic products and vaccines; and extracellular matrix hydrogel solution, a tissue engineered therapy for the treatment of Ulcerative Colitis. Additionally, it manufactures and sells foot and ankle surgical kits that include plates, screws, and tools; and distributes surgical supplies, orthopedic implants, artificial joints, and biologics, medical devices, and regenerative medicine products. It also serves as the general partner of the Management Services Organization. Generex Biotechnology Corporation was founded in 1983 and is headquartered in Miramar, Florida. On April 23, 2022, an involuntary petition for liquidation under Chapter 7 was filed against Generex Biotechnology Corporation in the U.S. Bankruptcy Court for the Southern District of Florida. On June 6, 2022, the involuntary petition was approved by the Court.
